Sun Pharma net profit rises 15 percent to Rs 2903 crore in Q3
New Delhi: Sun Pharmaceutical Industries reported a 15 percent on-year increase in consolidated net profit, reaching Rs 2,903 crore for the December quarter, driven by strong sales across geographies.
In the same period last year, the company had posted a net profit of Rs 2,524 crore.
Total revenue from operations rose to Rs 13,675 crore in the third quarter compared to Rs 12,381 crore in the year-ago period, Sun Pharma said in a regulatory filing.
The company said its board has declared an interim dividend of Rs 10.5 per share for the year FY25 against Rs 8.50 per share interim dividend for the previous year.
According to PTI, Sun Pharma Chairman and Managing Director Dilip Shanghvi said, "Our performance in the quarter showed all-round improvement. Product sales in Global Specialty crossed 1/5th of overall sales,"
"Our market share gain in India has been driven by industry-leading volume growth. Emerging Markets demonstrated strong performance in spite of currency challenges across geographies," he added.
All the company's businesses remain well-positioned for the future, Shanghvi stated.
The Mumbai-based drug maker said its formulation sales in India stood at Rs 4,300 crore in the December quarter, a growth of 13.8 per cent over the same period last fiscal and accounting for around 32 per cent of total consolidated sales.
Formulation sales in the US were at USD 474 million for the third quarter, a marginal dip as compared with the third quarter of last fiscal and accounting for around 30 per cent of the total consolidated sales.
Formulation sales in the emerging markets stood at USD 277 million in the third quarter, a year-on-year growth of 10 per cent and accounting for around 17 per cent of total consolidated sales.
Similarly, formulation sales in the Rest of World (ROW) markets, excluding India, the US and Emerging Markets, stood at USD 259 million in Q3FY25, a year-on-year growth of 21 per cent against the preceding fiscal.
External sales of API (Active Pharmaceutical Ingredient) were Rs 568 crore in Q3FY25, growing by 21.8 per cent over Q3 last year.
Sun Pharma shares ended 0.12 per cent lower at Rs 1,743.10 apiece on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.